Arcus Biosciences, Inc. (RCUS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Arcus Biosciences, Inc. (RCUS) closed at USD 22.53 on 2026-10-14, a change of +13.3 % over the past year, with a market capitalization of USD 2.91B.

Arcus Biosciences, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Arcus Biosciences, Inc. key figures

Previous close

USD 22.53 (2026-10-14)

1-year change

+13.3 %

Market cap

USD 2.91B

Enterprise value

USD 2.44B

P/E ratio (trailing)

-5.76

P/E ratio (forward)

-7.21

EPS (trailing)

-3.96

EPS (forward)

-3.17

PEG ratio

n/a

Price to book

6.25

Revenue growth

-74.4 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.66

Employees

601

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Arcus Biosciences, Inc. and compare it with other stocks.